# Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

> clinical trial · VERIFIED · 2026-08-24

Status: RECRUITING · Sponsor: National Cancer Institute (NCI) · Condition: Stage II Squamous Cell Carcinoma of the Head and Neck

- Company: National Cancer Institute (NCI)
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06161545

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.